Targeted mitochondrial function for cardiac fibrosis: An epigenetic perspective
- 2 January 2025
- journal article
- research article
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 228, 163-172
Abstract
No abstract availableKeywords
Funding Information
- Anhui Provincial Key Research and Development Plan (202104j07020037)
- Anhui Medical University (2020GMFY02)
- National Natural Science Foundation of China (81700212)
- National Natural Science Foundation of China (82170236)
- National Natural Science Foundation of China (82470281)
This publication has 75 references indexed in Scilit:
- Crosstalk between gut–brain axis: unveiling the mysteries of gut ROS in progression of Parkinson’s diseaseInflammopharmacology, 2024
- Mitochondrial targeted antioxidants as potential therapy for huntington’s diseasePharmacological Reports, 2024
- DNA hypomethylation by fisetin preserves mitochondria functional genes and contributes to the protection of I/R rat heartFunctional & Integrative Genomics, 2023
- Substitution of SERCA2 Cys674 aggravates cardiac fibrosis by promoting the transformation of cardiac fibroblasts to cardiac myofibroblastsBiochemical Pharmacology, 2022
- Cardiac fibrosis: Pathobiology and therapeutic targetsCellular Signalling, 2021
- LncRNA: Shedding light on mechanisms and opportunities in fibrosis and agingAgeing Research Reviews, 2019
- Involvement of the Warburg effect in non‐tumor diseases processesJournal of Cellular Physiology, 2017
- Mitochondrial DNA repair: a novel therapeutic target for heart failureHeart Failure Reviews, 2016
- Mitochondrial calpain system: An overviewArchives of Biochemistry and Biophysics, 2010
- A tale of two mitochondrial channels, MAC and PTP, in apoptosisApoptosis, 2007